ERCC1 (excision repair crosscomplementing 1) expression in pT2 Gallbladder cancer is a prognostic factor

Histology and Histopathology

Volumn 26, Issue 1, 2011, Pages 37-43

  Roa, Iván ^a   De Aretxabala, Xabier ^b   Lantadilla, Soledad ^a   Munoz, Sergio ^c  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

^b UNIVERSIDAD DEL DESARROLLO   (Chile)

^c UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

ERCC1; Gallbladder; Gallbladder cancer; Immunohistochemistry; Neoadjuvance; Survival

Indexed keywords

DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

AGED; ARTICLE; CANCER STAGING; CASE CONTROL STUDY; CHILE; FEMALE; GALLBLADDER TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROTEIN MICROARRAY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN ARRAY ANALYSIS;

EID: 78651225992     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Alberts S., Al-Khatib H., Mahoney M., Burgart L., Cera P. and Flynn P. J. (2005). Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma. A North Central Cancer Treatment Group phase II trial. Cancer 103, 111-118.
2. Albores-Saavedra J., Henson D. and Sobin L. (1992). The WHO Histological Classification of Tumors of the Gallbladder and Extrahepatic Bile Ducts. A commentary on the second edition. Cancer 70, 410-414.
3. American Joint Committee on Cancer. (2002). Gallbladder. In: AJCC Cancer Staging Manual. 6th ed. Springer. New York. NY. pp 139-144.
4. Andia M., Hsing A., Andreotti G. and Ferreccio C. (2008). Geographic variation of gallbladder cancer mortality and risk factors in Chile. A population-based ecologic study. Int. J. Cancer 123, 1411-1416.
5. Andrew A., Karagas M. and Hamilton J. (2003). Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water. Int. J. Cancer 104, 263-268.
6. Araujo S. and Wood R. (1999). Protein complexes in nucleotide excision repair. Mutat. Res. 435, 23-33.
7. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A. and Sharma A. (2006). RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24, 4731-4737.
8. Boulikas T. (1997). Nuclear import of DNA repair proteins. Anticancer Res. 17, 843-863.
9. Cheng L., Guan Y., Li L., Legerski R., Einspahr J., Bangert J., Albert D. and Wei Q. (1999). Expression in normal human tissues of five nucleotide excision repair genes measured simultaneously by multiplex reverse transcription-polymerase chain reaction. Cancer Epidemiol. Biomarkers Prev. 8, 801-807.
10. Cheng L., Spitz M., Hong W. and Wei Q. (2000). Reduced expression levels of nucleotide excision repair genes in lung cancer. A casecontrol analysis. Carcinogenesis 21, 1527-1530.
11. Chianale J., del Pino G. and Nervi F. (1990). Increasing gall-bladder cancer mortality rate during the last decade in Chile a high-risk area. Int. J. Cancer 46, 1131-1133.
12. de Aretxabala X., Roa I., Araya JC., Burgos L., Flores P. and Huenchullan I. (1990). Operative findings in patients with early forms of gallbladder cancer. Br. J. Surg. 77, 291-293.
13. de Aretxabala X., Roa I., Burgos L., Araya J., Villaseca M. and Silva J. (1997). Curative resection in potentially resectable tumours of the gallbladder. Eur. J. Surg. 163, 419-426.
14. Elpek G., Gelen T., Gulec F., Sedele M., Karpuzoglu T. and Suleymanlar I. (1999). Stereologic estimation of mean nuclear volume in well-differentiated adenocarcinoma and carcinoma in situ of the gallbladder. Anal. Quant. Cytol. Histol. 21, 445-448.
15. Gallardo J., Rubio B., Fodor M., Orlandi L., Yanez M., Gamargo C. and Ahumada M. (2001). A phase II study of gemcitabine in gallbladder carcinoma. Ann. Oncol. 12, 1403-1406.
16. Handra-Luca A., Hernandez J., Mountzios G., Taranchon E., Lacau-St-Guily J., Soria J. and Fouret P. (2007). Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin. Cancer Res. 13, 3855-3859.
17. Jun. H., Ahn M., Kim H., Yi S., Han J., Lee S., Ahn Y., Jeong H., Son Y., Baek J. and Park K. (2008). ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br. J. Cancer 99, 167-172.
18. Kapoor V. (2006). Gallbladder cancer. A global perspective. J. Surg. Oncol. 93, 607-609.
19. Latimer J., Nazir T., Flowers L., Forlenza M., Beaudry-Rodgers K., Kelly C., Conte J., Shestak K., Kanbour-Shakir A. and Grant S. (2003). Unique tissue-specific level of DNA nucleotide excision repair in primary human mammary epithelial cultures. Exp. Cell Res. 291, 111-121.
20. Lazcano-Ponce E., Miquel J., Munoz N., Herrero R., Ferrecio C., Wistuba I., Alonso de Ruiz P., Aristi-Urista G. and Nervi F. (2001). Epidemiology and molecular pathology of gallbladder cancer. CA. Cancer J. Clin. 51, 349-364.
21. Lee H., Han J., Kim J., Lee M., Jeong S., Kang S., Choi J., Oh Y., Park K., Hwang S., Sheen S. and Lim, H. (2008). Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 59, 95-104.
22. Liang B., Ross D. and Reed E. (1995). Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas. J. Neurooncol. 26, 17-23.
23. Martin L., Hamilton T. and Schilder R. (2008). Platinum resistance. the role of DNA repair pathways. Clin. Cancer Res. 14, 1291-1295.
24. Misra S., Chaturvedi A. and Misra N. C. (2006). Gallbladder cancer. Curr. Treat. Options. Gastroenterol. 9, 95-106.
25. Olaussen K. A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., Taranchon E., Filipits M., Pirker R., Popper H., Stahel R., Sabatier L., Pignon J., Tursz T., Le Chevalier T. and Soria J. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983-991.
26. Olaussen K. A., Mountzios G. and Soria J. C. (2007). ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr. Opin. Pulm. Med. 13, 284-289.
27. Reed E., Yu J., Davies A., Gannon J. and Armentrout S. (2003). Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin. Cancer Res. 9, 5299-5305.
28. Roa I., Araya J. C., Villaseca M., Roa J., de Aretxabala X. and Ibacache G. (1999). Gallbladder cancer in a high risk area. Morphological patterns. Hepatogastroenterology 46, 1540-1546.
29. Roa I., Araya J. C., Wistuba I. and de Aretxabala X. (1990). Gallbladder cancer. Anatomic and anatomo-pathologic considerations. Rev. Med. Chil. 118, 572-579.
30. Roa I., de Aretxabala X., Araya J. C., Villaseca M., Roa J., Gilda I. T., Burgos L. and Munoz S. (2002a). Morphological prognostic elements in gallbladder cancer. Rev. Med. Chil. 130, 387-395.
31. Roa I., de Aretxabala X., Roa J., Araya J. C., Villaseca M., Guzman P. and Burgos L. (2002b). Is gallbladder cancer a disease with bad prognosis? Rev. Med. Chil. 130, 1295-1302.
32. Rosell R., Cobo M., Isla D., Camps C. and Massuti B. (2006). Pharmacogenomics and gemcitabine. Ann. Oncol. 17, 13-16.
33. Rosell R., Cobo M., Isla D., Sanchez J., Taron M., Altavilla G., Santarpia M., Moran T., Catot S. and Etxaniza O. (2005). Applications of genomics in NSCLC. Lung Cancer 50, 33-40.
34. Rubin J. (1988). The molecular genetics of the incision step in the DNA excision repair process. Int. J. Radiat. Biol. 54, 309-365.
35. Serra I., Calvo A., Baez S., Yamamoto M., Endoh K. and Aranda W. (1996). Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer 78, 1515-1517.
36. Simon G., Sharma S., Cantor., Smith P and Bepler G. (2005). ERCC1 expression is a predictor of survival in resected patients with nonsmall cell lung cancer. Chest 127, 978-983.
37. Simon G., Ismail-Khan R. and Bepler G. (2007). Nuclear excision repairbased personalized therapy for non-small cell lung cancer. From hypothesis to reality. Int. J. Biochem. Cell. Biol. 39, 1318-1328.
38. Soria J. C. (2007). ERCC1-tailored chemotherapy in lung cancer. The first prospective randomized trial. J. Clin. Oncol. 25, 2648-2649.
39. Takenaka T., Yoshino I., Kouso H., Ohba T., Yohena T., Osoegawa A., Shoji F. and Maehara Y. (2007). Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int. J. Cancer 121, 895-900.
40. Taner C., Nagorney D. and Donohue J. (2004). Surgical treatment of gallbladder cancer. J. Gastrointest. Surg. 8, 83-89.
41. Vilmar A. and Sorensen J. (2009). Excision repair crosscomplementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin. A review of current literature. Lung Cancer 64, 131-139
42. Vogel U., Dybdahl M., Frentz G. and Nexo B. (2000). DNA repair capacity. inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat. Res. 461, 197-210.
43. Wistuba I. and Gazdar A. (2004). Gallbladder cancer lessons from a rare tumour. Nat. Rev. Cancer 4, 695-706.
44. Yagi T., Wood R. and Takebe H. (1997). A low content of ERCC1 and a 120 kDa protein is a frequent feature of group F xeroderma pigmentosum fibroblast cells. Mutagenesis 12, 41-44.
45. Yamaguchi A., Hachisuka K., Isogai M. and Tsubone M. (1992). Carcinoma in situ of the gallbladder with superficial extension into the Rokitansky-Aschoff sinuses and mucous glands. Gastroenterol. Jpn. 27, 765-772.
46. Zheng Z., Chen T., Li X., Haura E., Sharma A. and Bepler G. (2007). DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 356, 800-808.
47. Zindy P., Andrieux L., Bonnier D., Musso O., Langouet S., Campion J. P., Turlin B., Clement B. and Theret N. (2005). Upregulation of DNA repair genes in active cirrhosis associated with hepatocellular carcinoma. FEBS Lett. 579, 95-99.